In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Start-Up Previews (07/2007)

Executive Summary

A preview of the emerging health care companies profiled in the current, all-profiles issue of Start-Up. This month's profile groups are "Start-Ups in Obesity," "New Technologies for Infertility," and "New Zealand Biotech." Plus these Start-Ups Across Health Care: Intelect Medical, N Spine, and Solace Pharmaceuticals.

You may also be interested in...



Avandia and the Commercial Impact of FDA's Credibility Gap

GlaxoSmithKline's diabetes drug Avandia survived a perilous FDA advisory committee review. The real question is whether the industry can survive the damage to FDA's credibility.

Solace Pharmaceuticals Inc.

Solace Pharmaceuticals Inc. is pursuing identification and development of novel pain compounds based on the scientific work of its pedigreed founders. Launched just a little over a year ago, Solace has already taken its first steps for a Phase IIa proof-of-concept trial in neuropathic pain for its lead compound.

Incept BioSystems Inc.

With a microfluidics platform designed for cell biology, the founders of Incept BioSystems realized that they had the opportunity to improve the quality of embryos destined for in vitro fertilization. IVF represents a great first market for a small medtech company; and larger markets in cell therapy loom ahead for Incept.

Related Content

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

IV002981

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel